Target intelligence / Profile preview

Human metapneumovirus fusion protein (prefusion conformation) (hMPV F protein)

Target
hMPV F protein
Molecular classification
Viral fusion protein, Class I viral fusion protein, Envelope glycoprotein
01

Overview

The human metapneumovirus fusion protein (prefusion conformation) is a trimeric, class I viral fusion glycoprotein essential for mediating viral entry through membrane fusion. It is synthesized as an inactive precursor (F0), requiring proteolytic cleavage into F1 and F2 subunits which remain covalently linked. The prefusion conformation is the native state presented on viral particles prior to cell entry, and is the main target of potently neutralizing antibodies. Structural studies have shown the prefusion F exposes multiple key neutralizing epitopes, some conserved with related viruses such as respiratory syncytial virus (RSV). Its central role in infection, accessibility on the virus surface, and ability to elicit strong neutralizing immune responses make it the primary candidate for structure-based vaccine design and therapeutic antibody development against human metapneumovirus

Other names
hMPV F proteinHuman metapneumovirus F glycoproteinMetapneumovirus fusion glycoprotein
02

Mechanism of action

Neutralizing antibodies prevent membrane fusion and viral entry by binding to functional or antigenic sites on the prefusion F protein, stabilizing it, or preventing its conformational change required for fusion

03

Biological functions

Virus–cell membrane fusionMediating viral entry into host cellsInducing neutralizing antibody responses
04

Disease associations

Infection (specifically human metapneumovirus infection and associated lower respiratory tract diseases)
05

Safety considerations

Potential for vaccine-associated enhanced respiratory disease if improper conformation (e.g., postfusion vs. prefusion) is used in immunogens, though prefusion-stabilized F is being optimized specifically to minimize such risksGeneral risk of immune-mediated adverse events (not unique to this target)
06

Interacting drugs

None currently approved; several monoclonal antibodies (e.g., DS7, MPV196, 101F) are in preclinical/clinical evaluation as neutralizing agents
07

Biomarkers

Presence of antibodies to hMPV F in serum (serological marker of previous exposure or immunization)

Beyond the preview

Go deeper on Human metapneumovirus fusion protein (prefusion conformation) (hMPV F protein).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human metapneumovirus fusion protein (prefusion conformation) (hMPV F protein).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call